U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H12N2O
Molecular Weight 188.2258
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANTIPYRINE

SMILES

CN1N(C(=O)C=C1C)C2=CC=CC=C2

InChI

InChIKey=VEQOALNAAJBPNY-UHFFFAOYSA-N
InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3

HIDE SMILES / InChI

Molecular Formula C11H12N2O
Molecular Weight 188.2258
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Antipyrine is an analgesic and antipyretic that has been given by mouth and as ear drops. It is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. It inhibits cyclooxygenases and shows little anti-inflammatory activity. Like many old and approved substances after almost 100 years of use, antipyrine has been associated with some serious side effects, namely agranulocytosis and shock reactions.

Originator

Sources: DOI: 10.1016/S1366-0071(97)80033-2

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Finoten

Approved Use

Antipyrine is indicated for local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation: acute, congestive otitis media; otitis in influenza, the so-called viral bullous otitis; barotraumatic otitis.
Palliative
Unknown

Approved Use

Unknown
Primary
Antipyrine

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The radiological diagnosis of analgesic nephropathy.
1975 Jul
Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.
2001
Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
2001 Aug 16
A female with asymptomatic primary biliary cirrhosis associated with pernicious anemia.
2001 Dec
Determination of ototoxicity of common otic drops using isolated cochlear outer hair cells.
2001 Dec
Exercise-induced oxidative stress in older adults as measured by antipyrine oxidation.
2001 Dec
Derivative ratio spectra-zero crossing spectrophotometry and LC method applied to the quantitative determination of paracetamol, propyphenazone and caffeine in ternary mixtures.
2001 Dec
Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta.
2001 Feb
Experimental stroke in the female diabetic, db/db, mouse.
2001 Jan
Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes.
2001 Jan-Feb
Simultaneous measurement of cerebral blood flow and mRNA signals: pixel-based inter-modality correlational analysis.
2001 Jul 30
Synthesis of some triazolyl-antipyrine derivatives and investigation of analgesic activity.
2001 Jul-Aug
[Effect of hypoxic stress on xenobiotic metabolism and activities of various isoforms of cytochrome P-450].
2001 Jul-Aug
Metabolic functions of the liver during chemotherapy in children with acute lymphoblastic leukemia.
2001 Jun
Oxygen delivery at high blood viscosity and decreased arterial oxygen content to brains of conscious rats.
2001 Jun
Direct nuclear magnetic resonance spectroscopic analysis of (13)C-labeled antipyrine metabolites in human urine.
2001 Jun
Urine antipyrine metabolites in rats with different resistance to hypoxia subjected to cold stress.
2001 Mar
Comparison of cell inactivation by Auger electrons using the two reagents 4-[123I]iodoantipyrine and [123I]NaI.
2001 Mar
Quantitative analysis of rat inner ear blood flow using the iodo[(14)C]antipyrine technique.
2001 Mar
Analysis of sialo-N-glycans in glycoproteins as 1-phenyl-3-methyl-5-pyrazolone derivatives by capillary electrophoresis.
2001 Mar 2
[The liver monooxygenase system activity in the long-term compression syndrome and treatment with benzonal in prepubertal rats and rabbits].
2001 Mar-Apr
Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: transmembrane exchange and cytoplasmic binding process.
2001 May
In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery.
2001 May 18
Combined effects of acetaminophen, isopropylantipyrine and caffeine on pregnant and nonpregnant liver.
2001 Nov
Antioxidant supplementation and exercise-induced oxidative stress in the 60-year-old as measured by antipyrine hydroxylates.
2001 Nov
Phosphorylation of cyclic adenosine monophosphate response element binding protein in oligodendrocytes in the corpus callosum after focal cerebral ischemia in the rat.
2001 Oct
Theoretical considerations on the in vivo intestinal permeability determination by means of the single pass and recirculating techniques.
2001 Oct 23
Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
2001 Sep
Migraine, Midrin, and Imitrex.
2002 Apr
The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans.
2002 Apr
The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique.
2002 Apr
Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.
2002 Apr
Synthesis of syn and anti isomers of trans-cyclopropyl arginine.
2002 Apr 5
Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.
2002 Aug
Effect of the free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats.
2002 Aug 23
Exercise-induced oxidative stress in older adults as a function of habitual activity level.
2002 Feb
Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450.
2002 Feb
Transplacental transfer and metabolism of buprenorphine.
2002 Jan
Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry.
2002 Jan
Rational determination of transfer free energies of small drugs across the water-oil interface.
2002 Jan 3
Sequential morphological and permeability changes in the rete capillaries during hyperglycaemia.
2002 Jun 1
A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry.
2002 Jun 1
Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.
2002 Mar
Auto-protective redox buffering systems in stimulated macrophages.
2002 Mar 12
Probucol and liver efficiency during chemically-induced hepatocarcinogenesis.
2002 Mar-Apr
A new method for measuring oxidative stress in claudicants during strenuous exercise using free radical derivatives of antipyrine as indicators: a pilot study.
2002 Spring
Patents

Sample Use Guides

54 mg apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping.
Route of Administration: Otic (auricular)
In Vitro Use Guide
The influence of phenazone on the production of prostacyclin and thromboxane in human umbilical arteries was investigated by in vitro perfusion. With perfusate concentrations ranging from 10(-7) to 10(-4) M a decrease in the formation of both prostanoids was observed. The inhibitory effect of phenazone on prostanoid formation was found to be equal to that of indomethacin.
Substance Class Chemical
Created
by admin
on Fri Dec 15 14:58:01 GMT 2023
Edited
by admin
on Fri Dec 15 14:58:01 GMT 2023
Record UNII
T3CHA1B51H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANTIPYRINE
II   MI   USP   USP-RS   VANDF  
Common Name English
ANTIPYRINE [USP-RS]
Common Name English
ANTIPYRINE [VANDF]
Common Name English
PHENAZONE [EP IMPURITY]
Common Name English
PHENAZONE [MART.]
Common Name English
PHENAZONE [EP MONOGRAPH]
Common Name English
Phenazone [WHO-DD]
Common Name English
ANTIPYRINUM
HPUS  
Common Name English
2,3-Dimethyl-1-phenyl-3-pyrazolin-5-one
Systematic Name English
ANTIPYRINE [USP IMPURITY]
Common Name English
ANTIPYRINUM [HPUS]
Common Name English
phenazone [INN]
Common Name English
PHENAZONE
EP   INN   MART.   WHO-DD  
INN  
Official Name English
PROPYPHENAZONE IMPURITY A [EP IMPURITY]
Common Name English
ANTIPYRINE [JAN]
Common Name English
ANTIPYRINE [USP MONOGRAPH]
Common Name English
ANTIPYRINE [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC S02DA03
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
WHO-ATC N02BB71
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
WHO-VATC QS02DA03
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
FDA ORPHAN DRUG 5284
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
WHO-VATC QN02BB01
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
WHO-ATC N02BB01
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
WHO-VATC QN02BB51
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
WHO-VATC QN02BB71
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
WHO-ATC N02BB51
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
Code System Code Type Description
CHEBI
31225
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
MERCK INDEX
m1973
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID6021117
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
DRUG BANK
DB01435
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
FDA UNII
T3CHA1B51H
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
MESH
D000983
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
RXCUI
1001
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY RxNorm
PUBCHEM
2206
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
CAS
60-80-0
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
DAILYMED
T3CHA1B51H
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
DRUG CENTRAL
861
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
RS_ITEM_NUM
1040005
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
ChEMBL
CHEMBL277474
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
INN
413
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
WIKIPEDIA
PHENAZONE
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
LACTMED
Antipyrine
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
NCI_THESAURUS
C76794
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
EVMPD
SUB09753MIG
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
SMS_ID
100000085208
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-486-6
Created by admin on Fri Dec 15 14:58:01 GMT 2023 , Edited by admin on Fri Dec 15 14:58:01 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY